When medication after medication hasn’t worked, precisely dosed, CRNA-administered ketamine can bring relief in days — not weeks. 27,000+ infusions delivered since 2019.
Why MSKIT®?
MSKIT® is our protocol — developed by founder Charles Miller, CRNA — pairing sub-anesthetic IV ketamine with a calm, low-stimulation environment, NAD+ adjuncts, and structured follow-up. It consistently demonstrates the highest patient-reported relief of depressive symptoms across all ketamine administration modalities.
The Science
Chronic stress and trauma reduce the brain’s ability to communicate between neural pathways. Ketamine blocks NMDA receptors, triggering a glutamate surge that activates AMPA receptors and releases BDNF — opening a window of neuroplasticity in which the brain forms new, healthier connections.
Published randomized controlled research shows measurable improvement in depression severity within 24 hours of a single infusion (National Library of Medicine). Our protocols add NAD+ — the coenzyme every cell uses to create energy — to give your brain the biologic resources the neuroplastic window demands.
Calm is part of the protocol. A minimally stimulated environment lets the brain do its deepest work.
Conditions We Help Treat
MSKIT® protocols are tailored to mood disorders, chronic pain, or both:
Your Questions, Answered
Ketamine is an FDA-approved anesthetic that has been used safely in medical settings for over 60 years. The World Health Organization identifies it as one of the 100 most essential drugs in the world. Administered intravenously at sub-anesthetic doses, it can provide rapid relief from depressive symptoms with minimal side effects.
Ketamine blocks NMDA receptors, triggering a glutamate surge that activates AMPA receptors and stimulates the release of BDNF — increasing neuroplasticity. The neuroplastic window is strongest in the days after treatment, allowing the work you do outside the treatment room to take hold more effectively.
When administered by IV at the low dose required for neurogenesis, ketamine is not addictive. Other routes such as oral or intranasal use, or very high IV dosing, can sometimes lead to addiction — which is why CRNA-administered, precisely dosed treatment matters.
No. Ketamine is a dissociative, not a psychedelic — it produces a dream-like state similar to nitrous oxide rather than vivid perceptual distortions. Because it triggers the same neuroplastic response as psychedelics, it is categorized as a psychoplastogen.
At-home ketamine carries life-threatening risks because there is no medical oversight during administration — including laryngospasm, blood pressure changes, and impaired coordination. Our MSKIT® protocol uses precise dosing, continuous monitoring, anesthesia-level safety practices, and structured follow-up.
Depression, anxiety, PTSD, OCD, suicidal ideation, chronic pain, migraine, and symptoms related to long-COVID — as well as recovery from postoperative pain, injury-related pain, and traumatic brain injury (TBI).
Tell us a little about what you’re facing. A provider — not a salesperson — will reach out within one business day.
(423) 228-0579Prefer to visit first? Take the Google office tour · 7405 Shallowford Rd, Suite 240, Chattanooga, TN
Free & confidential
A provider — not a salesperson — will reach out within one business day.
Prefer to talk? (423) 228-0579
